144 filed Oct 30, 2026 at 16:28 ET
CEO Daniel O'Day filed a Form 144 notice of intent to sell 45,881 shares of Gilead Sciences common stock, with an approximate aggregate market value of $7.6 million based on the filing. The sale is planned for or around October 30, 2026, and includes shares acquired through stock option exercises and performance stock units. The filing is part of a pre-arranged 10b5-1 trading plan, which reduces the signal value of the insider sale signal.